A Phase 1/2 interventional study of Venetoclax and Dexamethasone in Relapsed/Refractory Multiple Myeloma, sponsored by AbbVie. Completed at 29 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-10.
Sponsored by AbbVie · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing venetoclax in Multiple Myeloma — 4 open to participants now, 9 under way, 2 of them phase 3. venetoclax · Multiple Myeloma.
Among the 20 studies testing venetoclax in Multiple Myeloma, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 1/2, and was the 1st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →4 of the 20 studies testing venetoclax in Multiple Myeloma are open now, in 3 countries. Recruiting first, the newest first:
Oncotherapeutics · Sites in United States
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
University of Miami · Sites in United States
Ages 18+
Melbourne Health · Sites in Australia
Ages 18–75
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 3
First in 2012; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 42 across the 20 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 20 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
40 studies in Multiple Myeloma by AbbVie: 7 open now, 17 under way, 5 of them phase 3. Of 21 finished, 8 (38%) have results posted.
Among the 40 studies in Multiple Myeloma by AbbVie, this one is the 17th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2012, is one of 7 in phase 1/2, and was the 8th registered.
AbbVie’s Multiple Myeloma studies by the year they started, since 2005.
4 of the studies testing venetoclax in Multiple Myeloma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05391750Emory UniversityVenetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | 2027-02-12 |
| NCT05853965Universitätsklinikum Hamburg-EppendorfCombination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma | 2027-04 |
| NCT02899052AbbVieStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies testing venetoclax in Multiple Myeloma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 40 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The Phase 1 primary objectives of this study were to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study also assessed the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma.
The Phase 2 primary objective was to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in participants with t(11;14)-positive multiple myeloma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of multiple myeloma (MM) previously treated with at least one .
For Phase 2, participants must have MM positive for the t(11;14) translocation, as determined by an analytically validated fluorescence in situ hybridization (FISH) assay per the central laboratory testing (enrollment with local t(11;14)-positive FISH results only will be considered at the discretion of the Therapeutic Area MD). Participants must have evidence of disease progression on or within 60 days of last dose of most recent previous treatment based on International Myeloma Working Group (IMWG) criteria AND must have previously received at least 2 lines of therapy, including an immunomodulatory drug (lenalidomide or pomalidomide), a proteasome inhibitor (bortezomib, carfilzomib or ixazomib), daratumumab, and .
at Screening:
Participants with a history of autologous or allogenic stem cell transplantation must have adequate peripheral blood counts independent of any growth factor support, and have recovered from any transplant related toxicity(s) and be:
Meet the following laboratory parameters, per the reference range, at least once during the screening period:
Exclusion Criteria:
Exhibits evidence of other uncontrolled condition(s), including, but not limited to:
History of other active other than multiple myeloma within the past 3 years prior to study entry, with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the dose-escalation cohort received 300 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
Drug: Venetoclax
Participants in the dose-escalation cohort received 600 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
Drug: Venetoclax
Participants in the dose-escalation cohort received 900 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
Drug: Venetoclax
Participants in the dose-escalation cohort received 1200 mg of venetoclax daily on Days 1 -21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
Drug: Venetoclax
Participants in the safety expansion cohort received 1200 mg of venetoclax daily on Days 1 - 21 of each cycle after a 2-week lead-in period, during which venetoclax doses were increased weekly.
Drug: Venetoclax
Participants with t(11;14) translocation multiple myeloma received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).
Drug: Venetoclax · Drug: Dexamethasone
The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).
Drug: Venetoclax · Drug: Dexamethasone
Each dose of venetoclax was to be taken with approximately 240 mL of water. On days that pre-dose pharmacokinetic (PK) sampling was required, dosing was to occur in the morning at the clinic at approximately 0900 (± 1 hour) to facilitate PK sampling. Dose Escalation cohort participants were to take venetoclax within 30 minutes after the completion of a standard low-fat breakfast with approximately 240 mL of water on Cycle 2 Day 1. On all other dosing days, participants were instructed to take venetoclax orally QD within 30 minutes after the completion of a low-fat breakfast. Tablets were to be swallowed whole and must not have been broken, chewed, or crushed.
Also known as: ABT-199, VENCLEXTA®
Tablets were administered by mouth per the dexamethasone prescribing information.
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From first dose of study drug until 30 days following last dose of study drug (up to 2482 days)
Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax
Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.
Time frame: Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose
Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax
Tmax is the the time at which the maximum plasma concentration (Cmax) is observed.
Time frame: Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose
Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax
AUC is a measure of how long and how much drug is present in the body after dosing.
Time frame: Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose (dose escalation cohort); (1200 mg dose): Cycle 2, Day 1 at predose (safety expansion cohort, 1200 mg dose)
Phase 2: Overall Response Rate
Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria.
Time frame: Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months
Phase 2: Very Good Partial Response Rate or Better
The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria was computed.
Time frame: Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months
Phase 1: Overall Response Rate
Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2011 International Myeloma Working Group (IMWG) criteria.
Time frame: Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 8.1 months
Time to Response (TTR)
TTR is defined as the number of days from the date of first dose of study drug until the date of their first favorable response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2011 International Myeloma Working Group (IMWG) criteria (Phase 1) or 2016 IMWG criteria (Phase 2). If a participant did not experience a favorable response, they were to be censored at the date of last adequate assessment. TTR was analyzed by Kaplan- Meier (K-M)\\ methodology.
Time frame: Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; Estimated median time on follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2
Time to Progression (TTP)
TTP is defined as the number of days from the date of first dose of study drug to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan- Meier (K-M) methodology.
Time frame: Estimated median duration of follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2
Duration of Response
DOR is defined as the number of days from the date of first response of Partial Response (PR) or better to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan- Meier (K-M) methodology.
Time frame: Assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median duration of follow-up was 8.1 months for Phase 1 and 31.7 months for Phase 2
Phase 2: Progression-Free Survival (PFS)
PFS is defined as the number of days from the date of the first dose of study treatment to the date of first documented disease progression or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.
Time frame: Estimated median duration of follow-up was 31.7 months
Phase 2: Overall Survival (OS)
OS is defined as the number of days from the date of the first dose of study drug to the date of death due to any cause. If a participant was not known to have died, OS was censored at the last known alive date. The distribution of OS was estimated using Kaplan-Meier methodology.
Time frame: Estimated median duration of follow-up was 31.7 months
Phase 2: Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain
The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its "worst in last 24 hours," "least in last 24 hours," "average," and "now" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.
Time frame: Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit
Phase 2: Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as "not at all" and 4 as "very much." The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.
Time frame: Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit
Phase 2: Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as "very poor" and 7 as "excellent." The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.
Time frame: Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit
Phase 2: Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score
PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \[PROMIS\] Cancer Fatigue Short Form \[SF\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.
Time frame: Baseline; Cycle 3, Day 1; Cycle 5, Day 1; Cycle 7, Day 1; Cycle 9, Day 1; Cycle 11, Day 1; Cycle 13, Day 1; Cycle 15, Day 1; Cycle 17, Day 1; Cycle 19, Day 1; Cycle 21, Day 1; Cycle 23, Day 1; Cycle 25, Day 1; Final visit
| Milestone | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|---|---|---|---|---|---|
| Started | 6 | 9 | 6 | 9 | 36 | 20 | 31 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 9 | 6 | 9 | 36 | 20 | 31 |
| Withdrew: Adverse events- related to progression | 0 | 0 | 1 | 2 | 0 | 1 | 0 |
| Withdrew: Adverse event- not related to progression | 1 | 1 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Progressive disease | 5 | 6 | 2 | 5 | 27 | 18 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Toxicity | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 0 | 1 | 0 | 7 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 22 |
| Withdrew: Other, not specified | 0 | 0 | 1 | 1 | 4 | 1 | 2 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| Participants | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|---|---|---|---|---|---|
| Any TEAE | 6 | 9 | 6 | 9 | 36 | 19 | 30 |
| TESAE | 1 | 4 | 3 | 3 | 15 | 6 | 16 |
Cmax is the highest concentration that a drug achieves in the blood after administration in a dosing interval.
| µg/mL | 300 mg Venetoclax | 600 mg Venetoclax | 900 mg Venetoclax | 1200 mg Venetoclax |
|---|---|---|---|---|
| Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax | 0.897 ± 0.593 | 2.56 ± 1.77 | 1.85 ± 1.30 | 4.16 ± 1.52 |
Tmax is the the time at which the maximum plasma concentration (Cmax) is observed.
| hours | 300 mg Venetoclax | 600 mg Venetoclax | 900 mg Venetoclax | 1200 mg Venetoclax |
|---|---|---|---|---|
| Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax | 5.0 (2.0 to 8.0) | 8.0 (2.7 to 8.0) | 6.0 (4.0 to 8.0) | 6.1 (4.0 to 8.0) |
AUC is a measure of how long and how much drug is present in the body after dosing.
| µg•h/mL | 300 mg Venetoclax | 600 mg Venetoclax | 900 mg Venetoclax | 1200 mg Venetoclax |
|---|---|---|---|---|
| Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax | 13.0 ± 8.31 | 38.2 ± 25.1 | 26.3 ± 20.1 | 71.5 ± 35.8 |
Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria.
| percentage of participants | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|
| Phase 2: Overall Response Rate | 48.4 (30.2 to 66.9) |
The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \[CR\], or Stringent complete response \[sCR\]) per 2016 standard International Myeloma Working Group (IMWG) criteria was computed.
| percentage of participants | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|
| Phase 2: Very Good Partial Response Rate or Better | 35.5 (19.2 to 54.6) |
Overall response rate is defined as the percentage of participants with documented best overall response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2011 International Myeloma Working Group (IMWG) criteria.
| percentage of participants | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|---|---|---|---|---|
| Phase 1: Overall Response Rate | 0 (0.0 to 45.9) | 11.1 (0.3 to 48.2) | 16.7 (0.4 to 64.1) | 0 (0.0 to 33.6) | 36.1 (20.8 to 53.8) | 65.0 (40.8 to 84.6) |
TTR is defined as the number of days from the date of first dose of study drug until the date of their first favorable response of Partial Response (PR) or better (PR, Very good partial response \[VGPR\], Complete response \[CR\], or Stringent complete response \[sCR\]) per 2011 International Myeloma Working Group (IMWG) criteria (Phase 1) or 2016 IMWG criteria (Phase 2). If a participant did not experience a favorable response, they were to be censored at the date of last adequate assessment. TTR was analyzed by Kaplan- Meier (K-M)\\ methodology.
| months | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|---|---|---|---|---|---|
| Time to Response (TTR) | — | NA (1.9 to NA) | NA (1.2 to NA) | — | 9.0 (1.9 to NA) | 2.6 (1.4 to NA) | 0.8 (0.7 to NA) |
TTP is defined as the number of days from the date of first dose of study drug to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. TTP was analyzed by Kaplan- Meier (K-M) methodology.
| months | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|---|---|---|---|---|---|
| Time to Progression (TTP) | 5.0 (3.9 to NA) | 2.0 (0.5 to NA) | 1.2 (0.4 to NA) | 1.9 (0.5 to NA) | 4.2 (1.9 to 10.2) | 12.2 (4.2 to 20.9) | 11.2 (5.2 to 18.4) |
DOR is defined as the number of days from the date of first response of Partial Response (PR) or better to the date of first documented disease progression or death due to multiple myeloma, whichever occurs first. DOR was analyzed by Kaplan- Meier (K-M) methodology.
| months | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|---|---|---|---|---|---|
| Duration of Response | — | 9.7 (NA to NA) | NA (NA to NA) | — | 17.3 (7.8 to 27.0) | 13.1 (5.7 to 21.9) | 17.5 (7.6 to 28.8) |
PFS is defined as the number of days from the date of the first dose of study treatment to the date of first documented disease progression or death due to any cause, whichever occurs first. PFS was analyzed by Kaplan-Meier methodology.
| months | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|
| Phase 2: Progression-Free Survival (PFS) | 11.2 (5.2 to 18.4) |
OS is defined as the number of days from the date of the first dose of study drug to the date of death due to any cause. If a participant was not known to have died, OS was censored at the last known alive date. The distribution of OS was estimated using Kaplan-Meier methodology.
| months | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|
| Phase 2: Overall Survival (OS) | 18.4 (8.2 to 24.3) |
The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its "worst in last 24 hours," "least in last 24 hours," "average," and "now" (current pain). For these items, participants are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine). The Worst Pain scores range from 0 to 10, with higher scores indicating severe pain. Negative changes from baseline indicate improvement.
| units on a scale | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|
| Cycle 3, Day 1 | 0.2 ± 2.47 |
| Cycle 5, Day 1 | -0.9 ± 1.43 |
| Cycle 7, Day 1 | -0.9 ± 1.20 |
| Cycle 9, Day 1 | -0.9 ± 1.46 |
| Cycle 11, Day 1 | -1.1 ± 1.62 |
| Cycle 13, Day 1 | 0.5 ± 3.84 |
| Cycle 15, Day 1 | -0.6 ± 1.27 |
| Cycle 17, Day 1 | -1.6 ± 1.29 |
| Cycle 19, Day 1 | -1.8 ± 2.00 |
| Cycle 21, Day 1 | -1.6 ± 2.30 |
| Cycle 23, Day 1 | -1.6 ± 2.30 |
| Cycle 25, Day 1 | -3.8 |
| Final visit | -0.3 ± 1.86 |
The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Physical Functioning scale, participants rate five items on a four-point scale, with 1 as "not at all" and 4 as "very much." The Physical Functioning Scale scores range from 0 to 100 and were calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high scale score represents high/healthy level of functioning. Positive changes from baseline indicate improvement.
| units on a scale | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|
| Cycle 3, Day 1 | -3.7 ± 21.90 |
| Cycle 5, Day 1 | 4.0 ± 15.78 |
| Cycle 7, Day 1 | 8.3 ± 11.13 |
| Cycle 9, Day 1 | 8.3 ± 11.13 |
| Cycle 11, Day 1 | 15.2 ± 9.97 |
| Cycle 13, Day 1 | 11.4 ± 14.76 |
| Cycle 15, Day 1 | 14.3 ± 11.17 |
| Cycle 17, Day 1 | 8.9 ± 13.11 |
| Cycle 19, Day 1 | -0.0 ± 11.55 |
| Cycle 21, Day 1 | -13.3 ± 28.28 |
| Cycle 23, Day 1 | -3.3 ± 14.14 |
| Cycle 25, Day 1 | 6.7 |
| Final visit | -5.0 ± 19.40 |
The QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including five functional scales (physical, role, emotional, social, and cognitive), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status/quality of life scale, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). For the Global Health Status/Quality of Life scale, participants rate two items on a seven point scale, with 1 as "very poor" and 7 as "excellent." The Global Health Status/Quality of Life scale ranges from 0 to 100 and was calculated per the EORTC QLQ-C30 Scoring Manual (3rd edition), version 3.0. A high score for the global health status/QoL represents a high QoL. Positive changes from baseline indicate improvement.
| units on a scale | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|
| Cycle 3, Day 1 | -5.2 ± 25.44 |
| Cycle 5, Day 1 | 6.7 ± 5.27 |
| Cycle 7, Day 1 | 3.1 ± 7.63 |
| Cycle 9, Day 1 | 8.3 ± 11.79 |
| Cycle 11, Day 1 | 0.0 ± 11.79 |
| Cycle 13, Day 1 | -6.0 ± 6.30 |
| Cycle 15, Day 1 | 4.8 ± 8.13 |
| Cycle 17, Day 1 | -1.4 ± 12.27 |
| Cycle 19, Day 1 | -19.4 ± 4.81 |
| Cycle 21, Day 1 | -33.3 ± 23.57 |
| Cycle 23, Day 1 | -8.3 ± 0.00 |
| Cycle 25, Day 1 | -8.3 |
| Final visit | -11.5 ± 23.55 |
PROMIS Cancer Fatigue SF is a seven item questionnaire that assesses the impact and experience of fatigue over the past 7 days. All questions employ the following five response options: 1 = Not at all, 2 = A little bit, 3 = Somewhat, 4 = Quite a bit, and 5 = Very much. The total raw score is the sum of the responses to each question and is converted to a T-score. The T-score re-scales the total raw score to a standardized score with a mean of 50 and a standard deviation of 10. The \[PROMIS\] Cancer Fatigue Short Form \[SF\] 7a T-Scores range from 29.4 to 83.2, with higher scores indicating more fatigue. Negative changes from baseline indicate improvement.
| T-score | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|
| Cycle 3, Day 1 | 0.6 ± 5.88 |
| Cycle 5, Day 1 | -2.9 ± 5.30 |
| Cycle 7, Day 1 | -1.8 ± 4.21 |
| Cycle 9, Day 1 | -1.6 ± 4.85 |
| Cycle 11, Day 1 | 0.1 ± 7.24 |
| Cycle 13, Day 1 | 1.0 ± 4.54 |
| Cycle 15, Day 1 | -3.4 ± 5.69 |
| Cycle 17, Day 1 | 0.6 ± 7.36 |
| Cycle 19, Day 1 | 6.6 ± 2.25 |
| Cycle 21, Day 1 | 11.6 ± 6.51 |
| Cycle 23, Day 1 | 6.0 ± 0.57 |
| Cycle 25, Day 1 | 5.6 |
| Final visit | 1.4 ± 6.51 |
Collected over All-cause mortality is reported from enrollment to end of study; median time on follow up was 6.6, 3.4, 3.8, 3.0, 11.0, 13.2, and 31.7 months for Phase 1 300 mg Ven, Phase 1 600 mg Ven, Phase 1 900 mg Ven, Phase 1 1200 mg Ven, Phase 1 Safety Expansion Ven 1200 mg, Phase 1 Combination Ven 800 mg/Dex, and Phase 2 Expansion Ven 800 mg/Dex, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Venetoclax 300 mg | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Phase 1: Venetoclax 600 mg | 1/9 (11.1%) | 4/9 (44.4%) | 9/9 (100%) |
| Phase 1: Venetoclax 900 mg | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Phase 1: Venetoclax 1200 mg | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| Phase 1 Safety Expansion: Venetoclax 1200 mg | 6/36 (16.7%) | 15/36 (41.7%) | 35/36 (97.2%) |
| Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | 1/20 (5%) | 6/20 (30%) | 19/20 (95%) |
| Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | 22/31 (71%) | 16/31 (51.6%) | 27/31 (87.1%) |
| Event | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|---|---|---|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 1/6 | 0/9 | 0/6 | 0/9 | 0/36 | 0/20 | 0/31 |
| PNEUMONIAInfections and infestations | 0/6 | 0/9 | 0/6 | 1/9 | 6/36 | 0/20 | 1/31 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 0/6 | 0/9 | 1/6 | 0/9 | 0/36 | 0/20 | 0/31 |
| BACK PAINMusculoskeletal and connective tissue disorders | 0/6 | 0/9 | 1/6 | 0/9 | 0/36 | 0/20 | 0/31 |
| MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/9 | 1/6 | 0/9 | 4/36 | 0/20 | 2/31 |
| RENAL FAILURERenal and urinary disorders | 0/6 | 0/9 | 1/6 | 0/9 | 0/36 | 0/20 | 0/31 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/6 | 1/9 | 0/6 | 0/9 | 0/36 | 0/20 | 0/31 |
| PAINGeneral disorders | 0/6 | 1/9 | 0/6 | 1/9 | 0/36 | 0/20 | 0/31 |
| PYREXIAGeneral disorders | 0/6 | 1/9 | 0/6 | 1/9 | 0/36 | 0/20 | 0/31 |
| RESPIRATORY TRACT INFECTION VIRALInfections and infestations | 0/6 | 0/9 | 0/6 | 1/9 | 0/36 | 0/20 | 0/31 |
| Event | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg |
|---|---|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 1/6 | 6/9 | 3/6 | 5/9 | 18/36 | 5/20 | 10/31 |
| DIARRHOEAGastrointestinal disorders | 2/6 | 4/9 | 2/6 | 5/9 | 13/36 | 7/20 | 12/31 |
| DIZZINESSNervous system disorders | 1/6 | 0/9 | 3/6 | 0/9 | 4/36 | 1/20 | 4/31 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/6 | 4/9 | 1/6 | 0/9 | 4/36 | 1/20 | 1/31 |
| VOMITINGGastrointestinal disorders | 1/6 | 4/9 | 2/6 | 2/9 | 4/36 | 2/20 | 5/31 |
| FATIGUEGeneral disorders | 2/6 | 1/9 | 0/6 | 2/9 | 15/36 | 2/20 | 9/31 |
| HYPOPHOSPHATAEMIAMetabolism and nutrition disorders | 0/6 | 1/9 | 1/6 | 0/9 | 6/36 | 8/20 | 3/31 |
| INSOMNIAPsychiatric disorders | 0/6 | 1/9 | 0/6 | 0/9 | 5/36 | 8/20 | 6/31 |
| WHITE BLOOD CELL COUNT DECREASEDInvestigations | 0/6 | 0/9 | 0/6 | 1/9 | 13/36 | 5/20 | 1/31 |
| ANAEMIABlood and lymphatic system disorders | 1/6 | 3/9 | 1/6 | 3/9 | 5/36 | 2/20 | 7/31 |
Intent-to-Treat (ITT) population: all participants who received at least one dose of study drug
| Age, Continuous(years) | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 62.0 ± 7.32 | 63.1 ± 9.03 | 61.8 ± 12.06 | 67.3 ± 8.32 | 60.8 ± 10.58 | 63.4 ± 8.13 | 64.9 ± 8.31 | 63.1 ± 9.25 |
| Sex: Female, Male(Participants) | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 5 | 5 | 23 | 3 | 13 | 52 |
| Male | 5 | 7 | 1 | 4 | 13 | 17 | 18 | 65 |
| Race/Ethnicity, Customized(Participants) | Phase 1: Venetoclax 300 mg | Phase 1: Venetoclax 600 mg | Phase 1: Venetoclax 900 mg | Phase 1: Venetoclax 1200 mg | Phase 1 Safety Expansion: Venetoclax 1200 mg | Phase 1 Combination: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg | Total |
|---|---|---|---|---|---|---|---|---|
| White | 6 | 9 | 4 | 6 | 34 | 17 | 24 | 100 |
| Black | 0 | 0 | 1 | 1 | 2 | 2 | 5 | 11 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Multi Race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Oct 2012 to primary completion in Nov 2021, 109 months.
Results were first posted in Apr 2023, 1 year 4 months after primary completion.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 109 months is above that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Venetoclax